This site is intended only for U.S. Healthcare Providers
Discover what Emgality® can do for patients with chronic migraine1
Actor portrayal
For your patients with ≥15 headache days per month1
Emgality reduced mean monthly MHDs1
Emgality prevented significantly more mean monthly MHDs vs placebo1a:
REGAIN: 4.8 with Emgality 120 mg (N=273) vs 2.7 with placebo (N=538) (baseline mean: 19.4 vs 19.6) over Months 1 to 3 (p<0.001)
Emgality demonstrated a reduction in MHDs in the first month and every following month1
Mean Change From Baseline in Monthly MHDs1,2a
aLS means and 95% confidence intervals are presented.1-3
bEarliest post-baseline, prespecified assessment.
In REGAIN, mean change from baseline in monthly MHDs with Emgality 120 mg (N=273) plus 240 mg loading dose vs placebo (N=538), respectively1,2a:
Month 1: -4.1b vs -1.8b
Month 2: -5.0 vs -3.0
Month 3: -5.4 vs -3.4
No formal hypothesis testing was conducted to evaluate treatment difference in mean monthly MHD reduction at each month. However, patients treated with Emgality 120 mg showed a nominally greater reduction in number of monthly MHDs at each month compared to placebo.1,2
Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.
For your patients with ≥15 headache days per month1
With Emgality, a significantly greater mean percentage of patients achieved a ≥50% reduction in monthly MHDs from baseline vs placebo (p<0.001)1
≥50% Reduction of Monthly MHDs From Baseline vs Placebo Over Months 1 to 31
cp<0.001 vs placebo.1
LS=least-square; MHD=migraine headache day.
Twenty-eightc percent of patients with chronic migraine taking Emgality 120 mg (N=273) achieved a ≥50% reduction in monthly MHDs from baseline vs 15% with placebo (N=538) over Months 1 to 3 (p<0.001).1
In REGAIN, Emgality 120 mg was not significantly better than placebo for the mean percentage of patients with ≥75% or 100% reduction from baseline in the number of monthly MHDs over the 3-month treatment period.1
Hypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with Emgality in clinical studies and the postmarketing setting. Cases of anaphylaxis and angioedema have also been reported in the postmarketing setting. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.
References
Emgality. Prescribing Information. Lilly USA, LLC.
Data on File. Lilly USA, LLC. DOF-GZ-US-0002.
Data on File. Lilly USA, LLC. DOF-GZ-US-0120.
IMPORTANT SAFETY INFORMATION
Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.
Hypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with Emgality in clinical studies and the postmarketing setting. Cases of anaphylaxis and angioedema have also been reported in the postmarketing setting. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.
Hypertension
Development of hypertension and worsening of pre-existing hypertension have been reported following the use of CGRP antagonists, including Emgality, in the postmarketing setting. Some of the patients who developed new-onset hypertension had risk factors for hypertension. There were cases requiring initiation of pharmacological treatment for hypertension and, in some cases, hospitalization. Hypertension may occur at any time during treatment but was most frequently reported within 7 days of therapy initiation. Emgality was discontinued in many of the reported cases.
Monitor patients treated with Emgality for new-onset hypertension or worsening of pre-existing hypertension, and consider whether discontinuation of Emgality is warranted if evaluation fails to establish an alternative etiology or blood pressure is inadequately controlled.
Raynaud’s Phenomenon
Development of Raynaud’s phenomenon and recurrence or worsening of pre-existing Raynaud’s phenomenon have been reported in the postmarketing setting following the use of CGRP antagonists, including Emgality. In reported cases with monoclonal antibody CGRP antagonists, symptom onset occurred after a median of 71 days following dosing. Many of the cases reported serious outcomes, including hospitalizations and disability, generally related to debilitating pain. In most reported cases, discontinuation of the CGRP antagonist resulted in resolution of symptoms.
Emgality should be discontinued if signs or symptoms of Raynaud’s phenomenon develop, and patients should be evaluated by a healthcare provider if symptoms do not resolve. Patients with a history of Raynaud’s phenomenon should be monitored for, and informed about the possibility of, worsening or recurrence of signs and symptoms.
The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.
Emgality is an injectable prescription medicine, available as:
prefilled single-dose pen with 120 mg/mL solution
prefilled single-dose syringe with 120 mg/mL solution
prefilled single-dose syringe with 100 mg/mL solution
